See more : SMS Co., Ltd. (SMSZF) Income Statement Analysis – Financial Results
Complete financial analysis of Izotropic Corporation (IZOZF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Izotropic Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Daewoong Co., Ltd. (003090.KS) Income Statement Analysis – Financial Results
- G2 Goldfields Inc. (GTWO.V) Income Statement Analysis – Financial Results
- China Oriental Group Company Limited (CUGCY) Income Statement Analysis – Financial Results
- Inventiva S.A. (IVEVF) Income Statement Analysis – Financial Results
- Sichuan Development Lomon Co., Ltd. (002312.SZ) Income Statement Analysis – Financial Results
Izotropic Corporation (IZOZF)
About Izotropic Corporation
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. The company was incorporated in 2016 and is headquartered in Surrey, Canada.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 59.07K | 30.88K | 6.87K | 1.63K | 3.28K | 6.54K | 4.54K | 0.00 |
Gross Profit | -59.07K | -30.88K | -6.87K | -1.63K | -3.28K | -6.54K | -4.54K | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 795.16K | 2.39M | 3.46M | 793.04K | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 654.55K | 2.32M | 2.04M | 3.67M | 933.15K | 251.87K | 526.37K | 58.56K |
Selling & Marketing | 116.61K | 427.66K | 759.57K | 225.52 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 771.16K | 2.74M | 2.80M | 3.67M | 933.15K | 251.87K | 526.37K | 58.56K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 1.57M | 5.33M | 6.61M | 4.98M | 1.16M | 398.54K | 705.40K | 72.69K |
Cost & Expenses | 1.57M | 5.33M | 6.61M | 4.98M | 1.16M | 398.54K | 705.40K | 72.69K |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 253.11K | 294.41K | 19.93K | 0.00 | 0.00 | 0.00 | 24.73K | 24.00K |
Depreciation & Amortization | 22.63K | 30.88K | 6.87K | 1.63K | 3.28K | 6.54K | 4.54K | 79.30K |
EBITDA | -1.60M | -5.22M | -6.34M | -4.82M | -1.07M | -311.01K | -594.37K | 0.00 |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -1.57M | -5.34M | -6.61M | -4.98M | -1.16M | -398.54K | -705.40K | -72.69K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 4.96K | -455.82K | -313.09K | -153.33K | -81.72K | -87.53K | -135.76K | -19.02K |
Income Before Tax | -1.56M | -5.66M | -6.65M | -4.98M | -1.16M | -398.54K | -730.13K | -98.32K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 294.41K | 19.93K | 4.00 | -2.00 | 3.00 | 0.00 | -55.30K |
Net Income | -1.56M | -5.66M | -6.65M | -4.98M | -1.16M | -398.54K | -730.13K | -98.32K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -0.03 | -0.11 | -0.15 | -0.14 | -0.05 | -0.02 | -0.03 | 0.00 |
EPS Diluted | -0.03 | -0.11 | -0.15 | -0.14 | -0.05 | -0.02 | -0.03 | 0.00 |
Weighted Avg Shares Out | 53.86M | 50.09M | 43.10M | 35.30M | 25.09M | 22.68M | 22.50M | 22.50M |
Weighted Avg Shares Out (Dil) | 53.86M | 50.09M | 43.10M | 35.30M | 25.09M | 22.68M | 22.50M | 22.50M |
Izotropic Provides Update on Annual General Meeting Materials and Voting Procedures
Izotropic Announces Regulatory Approval Plans to Launch Izoview for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU
Izotropic Corporation Announces Closing of First Tranche of Non-Brokered Private Placement
Izotropic Corporation Announces Non-Brokered Private Placement
Izotropic Receives Response From U.S. FDA
Izotropic Provides Regulatory and Operational Updates
Izotropic Completes Pre-Submission Meeting with U.S. FDA
Izotropic Closes Non-Brokered Private Placement
Izotropic Files Class II Pre-Submission with FDA & Releases Details on Predicate Devices
Izotropic Reaches Q3 Milestones and Provides Engineering Update
Source: https://incomestatements.info
Category: Stock Reports